Showing results (41-50 of 65) with videos related to

Sort By:
Pageof 7
Cell Reports. Medicine|December 20, 2023
Immunotherapy targeting B cells and long-lived plasma cells effectively eliminates pre-existing donor-specific allo-antibodiesZheng Zhang, Caroline Markmann, Ming Yu, et al.
Blood|August 22, 2024
Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapiesCyrille Touzeau, Amrita Y Krishnan, Philippe Moreau, et al.
Clinical Chemistry|August 12, 2021
Femtomolar SARS-CoV-2 Antigen Detection Using the Microbubbling Digital Assay with Smartphone Readout Enables Antigen Burden Quantitation and TrackingHui Chen, Zhao Li, Sheng Feng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 13, 2019
Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple MyelomaRobert F Cornell, Bonnie Ky, Brendan M Weiss, et al.
The Journal of Clinical Investigation|March 22, 2019
B cell maturation antigen-specific CAR T cells are clinically active in multiple myelomaAdam D Cohen, Alfred L Garfall, Edward A Stadtmauer, et al.
Medrxiv : the Preprint Server for Health Sciences|April 1, 2021
Femtomolar SARS-CoV-2 Antigen Detection Using the Microbubbling Digital Assay with Smartphone Readout Enables Antigen Burden Quantitation and Dynamics TrackingHui Chen, Zhao Li, Sheng Feng, et al.
Targeted Oncology|September 15, 2023
Population Pharmacokinetics and Exposure-Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1Xin Miao, Liviawati S Wu, Shun Xin Wang Lin, et al.
Cancer|January 4, 2026
Efficacy and safety of teclistamab in triple-class exposed relapsed/refractory multiple myeloma: Pooled findings from three clinical cohorts and a retrospective cohortThomas G Martin, María-Victoria Mateos, Jun Ho Yi, et al.
NEJM Evidence|May 22, 2024
CAR T-Cell Immunotherapy in Minority Patients with LymphomaGuido Ghilardi, Staci Williamson, Raymone Pajarillo, et al.
Blood Advances|December 19, 2023
Bendamustine lymphodepletion before axicabtagene ciloleucel is safe and associates with reduced inflammatory cytokinesGuido Ghilardi, Luca Paruzzo, Jakub Svoboda, et al.
Pageof 7